PolymarketVerificar disponibilidadeSem KYC2% de taxaProbabilidade implícita atualSim 12%-0.0%
Qualidade do mercado
52 / 100
Qualidade médiaVolume 24h
238,8 €
Liquidez
2,4 mil €
Liquidez médiaCompra / Venda
11.0% / 12.0%
Spread
9.1%
Spread amploVariação 7d
-4.5%
Dados do mercado
Atualizado há 5 minutos
12/01/26, 23:0931/12/26, 0:00
Tendências
Resultado escolhido
Yes12%
Também disponível em Kalshi
Will the FDA approve retatrutide?
11.0%6m
-11.0%17%
-7.0%85%
-7.0%87%
+2 mais resultados
28 • Baixa qualidadeSpread amploBaixa liquidezMercado raso
Volume total102 €
Volume 24h5,1 €
KALSHIRegras
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.
- This market will resolve to "Yes" if the U.S.
- Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
Os dados de comparação são apenas informativos. Preços e liquidez podem variar.
Mercados Relacionados
Hantavirus pandemic in 2026?
145,3 mil €Sim: 5%POLYMARKET
POLYMARKET
New pandemic in 2026?
16,6 mil €Sim: 10%POLYMARKET
POLYMARKET
Ebola pandemic in 2026?
8,7 mil €Sim: 8%POLYMARKET
POLYMARKET
How many movies will gross >$1 billion in 2026?
1,3 mil €0-3: 5.7%MANIFOLD MARKETS
MANIFOLD MARKETSWhich disease will be eradicated next in humans?
462,5 €Polio: 26.7%MANIFOLD MARKETS
MANIFOLD MARKETSAtivos nestes tópicos
Notícias Relacionadas
Chainalysis reveals $100 million peptide market built on cryptoCrypto News
Gray peptide vendors embrace stablecoins as safety fears deepenCrypto News
OpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.News
Brian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto NewsRegras
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more.
- This market will resolve to "Yes" if the U.S.
- Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’s for a drug product whose active ingredient is Eli Lilly’s retatrutide (including any brand name or identifier such as LY3437943) for any use between market creation and December 31, 2026, 11:59 PM ET.
- Otherwise, this market will resolve to "No."
- An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs